Nebenwirkungen · Capecitabine Medac
Capecitabine medac 150 mg film-coated tablets Capecitabine medac 500 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 16
HOS-218229 · Präparat HOS-216183
Capecitabine in combination therapy Table 5 lists ADRs associated with the use of capecitabine in combination with different chemotherapy regimens in multiple indications based on safety data from over 3,000 patients. ADRs are added to the appropriate frequency grouping (Very common or Common) according to the highest incidence seen in any of the major clinical trials and are only added when they were seen in addition to those seen with capecitabine monotherapy or seen at a higher frequency grouping compared to capecitabine monotherapy (see table 4). Uncommon ADRs reported for capecitabine in combination therapy are consistent with the ADRs reported for capecitabine monotherapy or reported for monotherapy with the combination medicinal product (in literature and/or respective summary of product characteristics).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-02T02:00:00Z · SHA-256 911762332dd30fd042dfa8a081c0eb1ec9e9d586a7284c79027e9cf3a76f4cf9 · Passage 1ea9d32fd2554f54aeaa7b518ada79f8c0f5792d2b4b5cf5cdc70c8dca1349ba · Zeichen 13379–14202 im Abschnitt